INARI MEDICAL, INC.

(NARI)
  Report
Real-time Estimate Cboe BZX  -  10:22 2022-06-30 am EDT
66.42 USD   -4.14%
06/24BTIG Adjusts Inari Medical's Price Target to $100 from $130, Keeps Buy Rating
MT
06/24INARI MEDICAL, INC.(NASDAQGS : NARI) added to Russell Small Cap Comp Value Index
CI
06/24INARI MEDICAL, INC.(NASDAQGS : NARI) added to Russell 3000E Value Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inari Medical Reports First Quarter 2022 Financial Results

05/04/2022 | 04:01pm EDT

IRVINE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2022.

First Quarter Revenue and Business Highlights:

  • Treated 8,800 patients, an increase of 14% sequentially over 7,700 patients treated in the fourth quarter of 2021.
  • Generated revenue of $86.8 million in the first quarter of 2022, up 4% sequentially and 51% over the same quarter last year.
  • Launched Intri24, an introducer sheath designed to optimize the FlowTriever procedure. Intri24 is the latest device added to our FlowTriever system of purpose-built tools, all for a single price.
  • Completed an offering of common stock, issuing 2.3 million shares and raising $174.4 million to strengthen our balance sheet and further accelerate investments in all five of our growth drivers.
  • Ended the quarter with $338.7 million in cash, cash equivalents and investments.

“We executed crisply across all five of our growth drivers during a highly productive first quarter,” said Bill Hoffman, CEO of Inari Medical. “We maintained our robust growth in patient treatments, presented important new data on the effectiveness of ClotTriever in patients with chronic clot, and raised additional capital to even further accelerate investment in our growth drivers. We also launched the Intri24, the second of what will be many product introductions this year. We are fully committed to better outcomes for our patients, and we remain honored and thankful to serve this mission.”   

First Quarter 2022 Financial Results

Revenue was $86.8 million for the first quarter of 2022, compared to $83.2 million for the prior quarter and $57.4 million for the first quarter of 2021. The increase over prior year was driven by continued U.S. commercial expansion and new product introductions.

Gross profit was $76.8 million for the first quarter of 2022, compared to $52.8 million for the same period of 2021. Gross margin was 88.5% for the first quarter of 2022, compared to 91.9% for the same period in the prior year, lower primarily due to the move to our larger production facility in the fourth quarter of 2021.

Operating expenses for the first quarter of 2022 were $79.9 million, compared to $45.1 million for the first quarter of 2021. The increase was mainly driven by personnel-related expenses as we increased headcount to fund the expansion of the commercial, research and development, and clinical and support organizations.

Net loss was $3.1 million for the first quarter of 2022 and net loss per share was $0.06 on a weighted-average basic and diluted share count of 51.0 million, compared to a net income of $7.5 million and a net income per share of $0.15 and $0.13 on a weighted-average basic share count of 49.4 million and diluted share count of 55.7 million, respectively, in the same period of the prior year.

Full-Year 2022 Revenue Guidance

Inari Medical is providing financial guidance as follows:

For the full year 2022, we are revising our revenue guidance to a range of $360 million to $370 million, an increase of $10 million from our original guidance range of $350 million to $360 million.

Webcast and Conference Call Information

Inari Medical will host a conference call to discuss the first quarter 2022 financial results after market close on Wednesday, May 4, 2022 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The conference call can be accessed live over the phone (833) 519-1265 for U.S. callers or (914) 800-3838 for international callers, using conference ID: 1854706. The live webinar can be accessed at https://ir.inarimedical.com.

About Inari Medical, Inc.

Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Our current product offering consists of two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.

Forward Looking Statements

Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements include estimated full year 2022 revenue, and are based on Inari’s current expectations, forecasts, and assumptions, are subject to inherent uncertainties, risks and assumptions that are difficult to predict, and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the period ended December 31, 2021, and in its other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.

Investor Contact:

ICR Westwicke
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com

INARI MEDICAL, INC.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share data)
(unaudited)

  Three Months Ended March 31, 
  2022  2021 
Revenue $86,752  $57,397 
Cost of goods sold  9,967   4,623 
Gross profit  76,785   52,774 
Operating expenses      
Research and development  16,135   8,163 
Selling, general and administrative  63,732   36,898 
Total operating expenses  79,867   45,061 
(Loss) income from operations  (3,082)  7,713 
Other income (expense)      
Interest income  50   68 
Interest expense  (73)  (73)
Other expenses  (24)  (41)
Total other expenses  (47)  (46)
(Loss) income before income taxes  (3,129)  7,667 
Provision for income taxes     198 
Net (loss) income $(3,129) $7,469 
Other comprehensive income (loss)      
Foreign currency translation adjustments  (117)  (180)
Unrealized (loss) gain on available-for-sale securities  (248)  18 
Total other comprehensive loss  (365)  (162)
Comprehensive (loss) income $(3,494) $7,307 
Net (loss) income per share      
Basic $(0.06) $0.15 
Diluted $(0.06) $0.13 
Weighted average common shares used to compute net
(loss) income per share
      
Basic  50,954,715   49,355,945 
Diluted  50,954,715   55,722,293 

INARI MEDICAL, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share data)
(unaudited)

  March 31,
2022
  December 31,
2021
 
Assets      
Current assets      
Cash and cash equivalents $186,556  $92,752 
Short-term investments  152,156   83,348 
Accounts receivable, net  44,950   42,351 
Inventories, net  23,828   21,053 
Prepaid expenses and other current assets  5,849   5,694 
Total current assets  413,339   245,198 
Property and equipment, net  18,153   16,471 
Operating lease right-of-use assets  46,401   44,909 
Deposits and other assets  6,216   981 
Long-term investments     3,983 
Total assets $484,109  $311,542 
Liabilities and Stockholders' Equity      
Current liabilities      
Accounts payable $6,066  $6,541 
Payroll-related accruals  19,729   24,433 
Accrued expenses and other current liabilities  9,155   10,737 
Operating lease liabilities, current portion  630   802 
Total current liabilities  35,580   42,513 
Operating lease liabilities, noncurrent portion  28,301   28,404 
Other long-term liability  1,416   1,416 
Total liabilities  65,297   72,333 
Commitments and contingencies (Note 7)      
Stockholders' equity      
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares
issued and outstanding as of March 31, 2022 and December 31, 2021
      
Common stock, $0.001 par value, 300,000,000 shares
authorized as of March 31, 2022 and December 31, 2021; 53,022,905
and 50,313,452 shares issued and outstanding as of March 31, 2022 and
December 31, 2021, respectively
  53   50 
Additional paid in capital  440,238   257,144 
Accumulated other comprehensive loss  (767)  (402)
Accumulated deficit  (20,712)  (17,583)
Total stockholders' equity  418,812   239,209 
Total liabilities and stockholders' equity $484,109  $311,542 
         


Primary Logo

Source: Inari Medical, Inc.

2022 GlobeNewswire, Inc., source Press Releases

All news about INARI MEDICAL, INC.
06/24BTIG Adjusts Inari Medical's Price Target to $100 from $130, Keeps Buy Rating
MT
06/24INARI MEDICAL, INC.(NASDAQGS : NARI) added to Russell Small Cap Comp Value Index
CI
06/24INARI MEDICAL, INC.(NASDAQGS : NARI) added to Russell 3000E Value Index
CI
06/24INARI MEDICAL, INC.(NASDAQGS : NARI) added to Russell 2500 Value Index
CI
06/24INARI MEDICAL, INC.(NASDAQGS : NARI) added to Russell 3000 Value Index
CI
06/24INARI MEDICAL, INC.(NASDAQGS : NARI) added to Russell 2000 Value Index
CI
06/24INARI MEDICAL, INC.(NASDAQGS : NARI) dropped from Russell 2000 Growth-Defensive Index
CI
06/24INARI MEDICAL, INC.(NASDAQGS : NARI) dropped from Russell 2000 Defensive Index
CI
06/21Inari Medical's Shares Rise After Piper Sandler Initiates Coverage
MT
06/21Piper Sandler Starts Inari Medical at Overweight With $100 Price Target
MT
More news
Analyst Recommendations on INARI MEDICAL, INC.
More recommendations
Financials (USD)
Sales 2022 365 M - -
Net income 2022 -38,5 M - -
Net cash 2022 316 M - -
P/E ratio 2022 -93,1x
Yield 2022 -
Capitalization 3 681 M 3 681 M -
EV / Sales 2022 9,22x
EV / Sales 2023 7,71x
Nbr of Employees 800
Free-Float 84,9%
Chart INARI MEDICAL, INC.
Duration : Period :
Inari Medical, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INARI MEDICAL, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 69,28 $
Average target price 105,00 $
Spread / Average Target 51,6%
EPS Revisions
Managers and Directors
William H. Hoffman President, Chief Executive Officer & Director
Mitchell C. Hill Chief Financial Officer
Don B. Milder Chairman
Thomas Tu Chief Medical Officer
Tara Dunn VP-Clinical Affairs & Market Development
Sector and Competitors
1st jan.Capi. (M$)
INARI MEDICAL, INC.-24.09%3 681
NOVOCURE LIMITED-3.57%7 572
MASIMO CORPORATION-53.18%7 555
SHOCKWAVE MEDICAL, INC.8.99%6 957
GETINGE AB-40.60%6 259
IRAY TECHNOLOGY COMPANY LIMITED-8.15%4 941